Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
50 Results for "
mutunt
" in MedChemExpress (MCE) Product Catalog:
Products (50)
50 Results for "mutunt" in MCE Product Catalog:
2
Target:
Research Areas:
Mutant IDH1-IN-1 (Agios 135) is a selective mutant IDH1 inhibitor with activity against both IDH1 R132H and IDH1 R132C. Mutant IDH1-IN-1 reduces the level of 2-hydroxyglutarate (2-HG), stabilizes mutant IDH1 protein, and restores blocked monocyte differentiation. Mutant IDH1-IN-1 can be used in tumor-related research .
2
2 Cited Publications
Synonyms: EGFR mutant-IN-3
Target:
Research Areas:
NT-1 (EGFR mutant-IN-3) is a potent mutant EGFR inhibitor and an analog of Osimertinib (HY-15772). This mutant EGFR inhibitor suppresses FGFR WT with an IC50 of 0.4 nM. NT-1 also inhibits EGFR L858R, EGFR Exon 19 deletion and EGFR T790M. NT-1 exerts deeper inhibition on p-EGFR and p-ERK, and induces tumor cell apoptosis. NT-1 can be used in colorectal cancer research .
2
2 Cited Publications
Target:
Research Areas:
Mutant IDH1 inhibitor is a potent mutant IDH1 R132H inhibitor with IC50 of < 72 nM.
2
2 Cited Publications
Cat. No.: HY-18717
CAS No.: 1429176-69-1
Target:
Research Areas:
Mutant IDH1-IN-2 is a inhibitor of mutant Isocitrate dehydrogenase (IDH) proteins, with IC50 of in LS-MS biochemical assay, IC50 of 16.6 nM in Fluorescence biochemical assay.
1
1 Cited Publications
Mutant p53 modulator-1 is a mutant p53 modulator. Mutant p53 modulator-1 reduces the progression of cancers that contain a p53 mutation (extracted from patent WO2021231474A1, compound 231B) .
Cat. No.: HY-D1056C5
Synonyms: LPS, from Salmonella enterica (Serotype minnesota Re 595 (Re mutant))
It is recommended to prepare a solution with concentration ≥2 mg/mL. Vortex thoroughly for more than 10 minutes. Due to the adsorption characteristics of LPS, silanized container or low adsorption centrifuge tubes should be used for aliquoting and storage, and mix thoroughly before use.
Cat. No.: HY-E70884
Synonyms: EndoS2 D184M
Target:
Research Areas:
Endoglycosidase S2 (D184M mutant) (EndoS2 D184M) is a mutant endoglycosidase. Endoglycosidase S2 (D184M mutant) promotes the transfer of glyco-oxazoline donors with defined glycoforms to the Fc region of IgG antibodies .
Cat. No.: HY-131312
CAS No.: 2230263-60-0
Synonyms: LY3410738; Mutant IDH1-IN-6
Target:
Research Areas:
Mutant IDH1-IN-6 is a potent, selective and orally active mutant isocitrate dehydrogenase (IDH) inhibitor with IC50s of 6.27 nM, 3.71 nM, 36.9 nM and 11.5 nM for IDH1 R132H, IDH1 R132C, IDH2 R140Q and IDH2 R172K mutant enzymes, respectively. Mutant IDH1-IN-6 is less active at inhibiting the IDH wild-type enzymes .
Cat. No.: HY-E70879
Synonyms: EndoM N175Q
Target:
Research Areas:
Endoglycosidase M (N175Q mutant) (EndoM N175Q) can transfer natural N-glycans or oxazoline N-glycans to any peptide or protein with a GlcNAc residue to form a β1-4-glycosidic linkage. Endoglycosidase M (N175Q mutant) is a useful tool in the synthesis of homogeneous glycopeptides and glycoproteins .
Cat. No.: HY-E70883
Synonyms: EndoS D233Q
Target:
Research Areas:
Endoglycosidase S (D233Q mutant) (EndoS D233Q) is a mutant endoglycosidase, which catalyzes the glycosylation of Trastuzumab (HY-P9907)-GlcNAc with the functionalized, non-natural glycans to give glycosylated monoclonal Abs (mAbs) carrying two glycans each functionalized with two reaction handles .
Cat. No.: HY-126298
CAS No.: 2340020-82-6
RAF mutant-IN-1 is a RAF kinase inhibitor, extracted from patent WO2019107987A1, with IC50 values of 21 nM, 30 nM and 392 nM for C-RAF 340D/Y341D, B-RAF V600E and B-RAF WT, respectively .
Cat. No.: HY-114459
CAS No.: 1416270-18-2
Target:
Research Areas:
Mutant IDH1-IN-4 (compound 434) is an inhibitor of mutant Isocitrate dehydrogenase 1 (IDH 1), with IC50 values of ≤ 0.5 μM for mutant IDH1 in R132H, HT1080 and U87R132H cells .
Cat. No.: HY-175213
Target:
Research Areas:
Mutant IDH1-IN-7 is a highly selective Isocitrate Dehydrogenase 1 (IDH1) R132H (IC50 = 0.26 μM, Kd = 2.1 μM)/R132C (IC50 = 1.1 μM) inhibitor. Mutant IDH1-IN-7 has no inhibitory effect on wild-type IDH1, IDH2-wt, and IDH2 R140Q. Mutant IDH1-IN-7 inhibits 2-Hydroxyglutarate (2-HG) production in U87-MG R132H cells (EC50 = 0.55 μM). Mutant IDH1-IN-7 exhibits moderate antiproliferative effects on U87-MG R132H and HT-1080 cells .
Cat. No.: HY-132920
CAS No.: 2642630-16-6
KRAS mutant protein inhibitor 1 is a KRAS mutant protein inhibitor for potential research in cancer.
Cat. No.: HY-E70880
Synonyms: EndoCC N180H
Target:
Research Areas:
Endoglycosidase CC (N180H mutant) (EndoCC N180H) is a mutant endoglycosidase, which efficiently and specifically recognizes core fucose and O-GlcNAc .
Cat. No.: HY-131312A
CAS No.: 2759438-85-0
Synonyms: LY3410738 gentisate; Mutant IDH1-IN-6 gentisate
Target:
Research Areas:
Crelosidenib (gentisate) is a potent, selective and orally active mutant isocitrate dehydrogenase (IDH) inhibitor with IC50 of 6.27 nM, 3.71 nM, 36.9 nM and 11.5 nM for IDH1 R132H, IDH1 R132C, IDH2 R140Q and IDH2 R172K mutant enzymes, respectively. Crelosidenib (gentisate) is less active at inhibiting the IDH wild-type enzymes .
Cat. No.: HY-E70881
Synonyms: EndoF3 D165A
Target:
Research Areas:
Endoglycosidase F3 (D165A mutant) (EndoF3 D165A) is a mutant endoglycosidase, which efficiently and specifically recognizes core fucose and O-GlcNAc .
EGFR mutant-IN-2 (Compound D51) is an EGFR mutant inhibitor. EGFR mutant-IN-2 inhibits the EGFR L858R/T790M/C797S mutant with an IC50 value of 14 nM. EGFR mutant-IN-2 inhibits the EGFR del19/T790M/C797S mutant with an IC50 value of 62 nM. EGFR mutant-IN-2 has favorable PK parameters, safety properties, in vivo stability, and antitumor activity .
Cat. No.: HY-100476
CAS No.: 1648909-73-2
Target:
Research Areas:
Mutant IDH1-IN-3 (Compound 1) is a selective allosteric inhibitor of mutant isocitrate dehydrogenase 1 (IDH1). Mutant IDH1-IN-3 has an IC50 of 13 nM for R132H IDH1. Mutant IDH1-IN-3 inhibits the production of D-2-hydroxyglutaric acid (2HG) in cells. Mutant IDH1-IN-3 can be used in the study of cancer .
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
